

Recurrent *FOSL1* rearrangements in desmoplastic fibroblastoma

Solange De Noon^{1,2}, Robert Piggott³, Jamie Trotman³, John A Tadross^{3,4,5}, Matthew Fittall^{6,7}, Debbie Hughes⁸, Hongtao Ye², Emani Munasinghe², Matthew Murray^{9,10}, Roberto Tirabosco², Fernanda Amary², Nicholas Coleman¹⁰, James Watkins^{3,4}, Michael Hubank^{11,12}, Patrick Tarpey³, Sam Behjati^{9,13,14*} and Adrienne M Flanagan^{1,2*†}

¹ Research Department of Pathology, University College London Cancer Institute, London, UK

² Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK

³ Cambridge Genomics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

⁴ Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

⁵ MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK

⁶ Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK

⁷ Division of Oncology, University College London Cancer Institute, London, UK

⁸ Paediatric Tumour Biology, Division of Clinical Studies, The Institute of Cancer Research, London, UK

⁹ Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

¹⁰ Department of Pathology, University of Cambridge, Cambridge, UK

¹¹ Clinical Genomics, The Royal Marsden NHS Foundation Trust, London, UK

¹² Molecular Pathology, The Institute of Cancer Research, London, UK

¹³ Cellular Genetics, Wellcome Sanger Institute, Hinxton, UK

¹⁴ Department of Paediatrics, University of Cambridge, Cambridge, UK

*Correspondence to: S Behjati, Cellular Genetics, Wellcome Sanger Institute, Hinxton CB10 1SA, UK. E-mail: sb31@sanger.ac.uk; AM Flanagan, Department of Pathology, University College London Cancer Institute, London, UK. E-mail: a.flanagan@ucl.ac.uk

†These authors jointly supervised this work.

Abstract

The *FOS* gene family has been implicated in tumorigenesis across several tumour types, particularly mesenchymal tumours. The rare fibrous tumour desmoplastic fibroblastoma is characterised by overexpression of *FOSL1*. However, previous studies using cytogenetic and molecular techniques did not identify an underlying somatic change involving the *FOSL1* gene to explain this finding. Prompted by an unusual index case, we report the discovery of a novel *FOSL1* rearrangement in desmoplastic fibroblastoma using whole-genome and targeted RNA sequencing. We investigated 15 desmoplastic fibroblastomas and 15 fibromas of tendon sheath using immunohistochemistry, *in situ* hybridisation and targeted RNA sequencing. Rearrangements in *FOSL1* and *FOS* were identified in 10/15 and 2/15 desmoplastic fibroblastomas respectively, which mirrors the pattern of *FOS* rearrangements observed in benign bone and vascular tumours. Fibroma of tendon sheath, which shares histological features with desmoplastic fibroblastoma, harboured *USP6* rearrangements in 9/15 cases and did not demonstrate rearrangements in any of the four *FOS* genes. The overall concordance between *FOSL1* immunohistochemistry and RNA sequencing results was 90%. These findings illustrate that *FOSL1* and *FOS* rearrangements are a recurrent event in desmoplastic fibroblastoma, establishing this finding as a useful diagnostic adjunct and expanding the spectrum of tumours driven by *FOS* gene family alterations. © 2022 The Authors. *The Journal of Pathology* published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Keywords: *FOSL1*; *FOS*; desmoplastic fibroblastoma; targeted sequencing; gene rearrangement

Received 23 September 2022; Revised 2 November 2022; Accepted 23 November 2022

No conflicts of interest were declared.

Introduction

The discovery of the *FOS* retroviral homologue (v-fos) as an initiator of osteosarcoma in mice [1] spurred significant interest in the role of *FOS* and its paralogues in the pathogenesis of bone and other tumours. The *FOS* gene family comprises four genes, *FOS*, *FOSB*, *FOSL1* and *FOSL2*, which encode subunits of the activator protein

1 (AP1) transcription factor, a master regulator of human development and cellular differentiation [2,3]. Cancer genomics efforts over the past decade have revealed that somatic rearrangements in *FOS* and *FOSB* underpin osteoblastoma [4], osteoid osteoma, epithelioid haemangioma [5,6] and pseudomyogenic haemangioendothelioma [7]. Mutations of the remaining two *FOS* genes, *FOS Like 1* (*FOSL1*) and *FOS Like 2* (*FOSL2*), have

not been demonstrated in human tumours to date. In particular, although the benign fibrous tumour desmoplastic fibroblastoma (collagenous fibroma) is characterised by *FOSL1* overexpression [8], cytogenetic studies have localised recurrent breakpoints to chromosome 11q12, adjacent to but not involving the *FOSL1* gene [8–10].

Here we outline the initial discovery by whole-genome sequencing of a *FOSL1* rearrangement that recapitulates the pattern of reported *FOS* variants in an index case of desmoplastic fibroblastoma. We further demonstrate that rearrangements in *FOSL1* and, less commonly *FOS* represent a recurrent and specific feature in the majority of these tumours.

Materials and methods

Whole-genome sequencing (index case)

Fresh frozen tumour and whole blood were submitted for whole-genome sequencing through the National Health Service (NHS) Genomic Medicine Service via the East Genomics Laboratory Hub (GLH), Cambridge, UK, as previously described [11]. Data processing and analysis were performed using the established clinical pipeline at the East GLH. All data presented for the index case were generated as part of routine clinical care. The child's legal guardians provided informed consent for publication of their child's case. The validation cohort was obtained through the University College London/University College London Hospitals (UCL/UCLH) Biobank for Health and Disease (REC reference 20/YH/0088).

Targeted RNA sequencing

Archival formalin-fixed paraffin-embedded (FFPE) material from 15 cases each of desmoplastic fibroblastoma and fibroma of tendon sheath were obtained from the UCL/UCLH tissue biobank at the Royal National Orthopaedic Hospital (RNOH). RNA was extracted from

tumour FFPE material and analysed using the TruSight[®] RNA Pan-Cancer Panel (Illumina, San Diego, CA, USA) according to the manufacturer's protocol. This panel allows for targeted enrichment of the exonic sequences of 1,385 cancer-related genes, including *FOS*, *FOSB*, *FOSL1* and *USP6*. Bioinformatic analysis was performed using the RNA-Seq Alignment App version 2.0.1 (BaseSpace Sequencing Hub, Illumina) with default parameters (Supplementary materials and methods). This was followed by analysis using a second, clinically validated in-house pipeline based on Arriba [12] at the North Thames GLH. Sequencing data were manually inspected for reads supporting breakpoints across the four *FOS* genes using the Integrative Genomics Viewer [13].

Immunohistochemistry and FISH analysis

All samples were subjected to *FOSL1* immunohistochemistry using Anti-Fra-1 (C-12, Santa Cruz Biotechnologies, Texas, USA, see Supplementary materials and methods). c-*FOS* immunohistochemistry was performed using Anti-c-Fos (ABE457, 0.5 µg/ml, MilliporeSigma, Burlington, MA, USA). Fluorescence *in situ* hybridisation (FISH) analysis for *USP6* breakpoints was performed on all fibromas of tendon sheath samples with commercially available *USP6* dual colour probe (Zytovision, Bremerhaven, Germany).

Results

This study began with a case of an infant who had developed an infiltrative mass in the dorsal compartment of the distal forearm, near the wrist. This mass was initially noted during the first few weeks of life; progressive growth for several months prompted an open biopsy at a separate hospital. Histology demonstrated a bland, hypocellular spindle cell tumour with a myxocollagenous stroma, which lacked informative diagnostic features on immunohistochemistry. No convincing evidence of malignancy was observed, but a low-grade sarcoma could




Figure 1. *FOSL1* rearrangement in index case. (A) Overview of somatic copy number and structural variant analysis of index tumour whole genome, including t(11;14)(q13.1;q22.1) rearrangement involving *FOSL1*. Green indicates absolute copy number, yellow minor allele copy number. (B) Schematic of *FOSL1* rearrangement. Transcript sequence shows introduction of premature stop codon. (C) Haematoxylin and eosin (H&E) showed a paucicellular fibrous lesion composed of bland spindle cells, which demonstrated strong nuclear immunoreactivity to *FOSL1* (inset).




Figure 2. *FOSL1* and *FOS* rearrangements in desmoplastic fibroblastoma. (A) Schematic of *FOS* gene family transcripts showing shared pattern of breakpoints in *FOS* and *FOSL1*, leading to detachment of the proteasome degradation motif. HR, homologous region; D-TAD, dominant transactivation domain; DBD, DNA binding domain; LZ, leucine zipper region. (B) Clustering of *FOSL1* breakpoints detected in desmoplastic fibroblastoma in exon 4 of gene. (C–E) Correlation of immunohistochemical and targeted RNA sequencing results. Strong diffuse immunoreactivity for (C) *FOSL1* or (D) *FOS* were associated with the presence of rearrangements in the respective genes. (E) Weak and partial *FOSL1* expression was seen in some fibromas of tendon sheaths, but typical *USP6* rearrangements and absence of *FOSL1* rearrangements distinguish these tumours.

not be excluded. Given surgical options for *en bloc* removal without functional impairment were limited, chemotherapy was proposed as is commonly employed in unresectable, low-grade fibromatous tumours of childhood. The child then came under our care, at which time the growth of the lesion had stabilised. A decision was made to monitor the tumour closely before embarking on definitive treatment. Nine months later the mass increased in size, and the lesion was excised. At this time, the diagnosis of a benign fibrous tumour could be provided with greater confidence; the favoured differential diagnoses included a fibroma of tendon sheath and desmoplastic fibroblastoma (Figure 1C). No histological features of malignancy were identified.

Clinical whole-genome sequencing, performed through the NHS Genomic Medicine Service, revealed a rearrangement involving the *FOSL1* gene on chromosome 11 (Figure 1A). The *FOSL1* breakpoint was located in the final exon of the gene, with the partner sequence belonging to an intergenic region on chromosome 14. The location of this breakpoint ostensibly disconnects the functional coding sequences from its terminal regulatory domain, mirroring the pattern of rearrangements previously described in *FOS* [4,6]. The tumour genome was otherwise devoid of somatic copy number changes or point mutations that generated plausible driver events. Targeted RNA sequencing, performed on FFPE-derived cDNA using TruSight[®] RNA Pan-Cancer Panel, confirmed the *FOSL1* breakpoint at the transcript level (Figure 1B), which was further corroborated by strong nuclear immunoreactivity for FOSL1 (Figure 1C). Based on these findings, a final diagnosis of desmoplastic fibroblastoma was concluded, and we speculated that somatic *FOSL1* rearrangements may underpin desmoplastic fibroblastoma.

We investigated 15 additional cases of desmoplastic fibroblastoma by targeted sequencing of FFPE-derived cDNA and correlated the transcriptomic findings with immunohistochemistry for FOSL1 (supplementary material, Table S1). In a cohort of 15 desmoplastic fibroblastomas, we found strong FOSL1 immunopositivity in 12/15 cases (including one recurrent tumour DF10), 10 of which harboured *FOSL1* rearrangements at the transcript level (Figure 2, supplementary material, Table S2). The remaining 3/15 cases did not exhibit FOSL1 immunoreactivity or *FOSL1* rearrangements. Similar to the index case, all *FOSL1* breakpoints clustered around the regulatory domain of the final exon (Figure 2A,B). Rearrangement partners were scattered across multiple chromosomes, most commonly chromosome 2 ($n = 4$), and all comprised non-coding regions, either intronic (out of reading frame, $n = 5$) or intergenic ($n = 5$). Despite strong FOSL1 expression in two cases, DF11 and DF12, these revealed no evidence of rearrangements in *FOSL1*.

We next delved into the three *FOSL1* wild-type and immunonegative cases of desmoplastic fibroblastoma and found that two of these contained breakpoints in the final exon of *FOS*, identical to the recurrent alterations that typify osteoblastoma (Figure 2A). Consistent with this finding, we demonstrated *c-FOS* immunoreactivity

in both cases (Figure 2D). In the third *FOSL1* wild-type case (DF15), an intrachromosomal *TFG-PIK3CA* translocation was identified.

To explore the specificity of these findings in *FOS* and *FOSL1* for desmoplastic fibroblastoma, we examined 15 fibroma of tendon sheath tumours, their principal histological mimic. As 90% of these contain *USP6* rearrangements [14], we submitted all cases for FOSL1 immunohistochemistry and FISH for a *USP6* break-apart signal. Nine fibromas of tendon sheath harboured *USP6* break-apart signals (Figure 2E). FOSL1 immunostaining was negative in 12/15 cases, whereas 3/15 (FTS5, FTS11, FTS12) showed equivocal weak nuclear immunoreactivity (1+) with a minor population of tumour cells demonstrating stronger (2+/3+) positivity (Figure 2E). No fibromas showed strong uniform FOSL1 positivity, as observed in desmoplastic fibroblastoma. We interrogated the six fibromas of tendon sheath, which showed no *USP6* rearrangement by FISH, using targeted RNA sequencing, and did not find a breakpoint in *FOSL1* or any of the other three *FOS* genes. Across both tumour types, concordance between FOSL1 immunohistochemistry and targeted sequencing results was 90%. Together, these findings indicated that *FOSL1* rearrangements, detectable by immunohistochemistry or direct sequencing of the *FOSL1* transcript, are a common feature in desmoplastic fibroblastoma and absent from fibroma of tendon sheath, including *USP6* wild-type cases.

Discussion

Our investigation revealed that a majority of desmoplastic fibroblastomas harbour rearrangements in *FOSL1* that distinguish them from their main mimic, fibroma of tendon sheath. Although conventional morphology alone will suffice in most cases to reach a diagnosis of desmoplastic fibroblastoma, some rare cases will require more definitive evidence to aid clinical decision making, as illustrated by the index patient of this study. The finding of a molecular marker that confirmed the benign nature of this tumour-directed clinical management to prioritise long-term functional outcomes over tumour eradication. In addition, identification of *FOSL1* rearrangements has allowed confirmation of a case of locally recurrent desmoplastic fibroblastoma (DF10). Disease relapse has not been reported in the literature for this tumour type, so our finding expands the spectrum of clinical behaviour displayed by this entity.

Similar to the need for cautious interpretation of FOS and FOSB immunoreactivity [15,16], careful optimisation of the dilution of antibodies against FOSL1 is required since wild-type cells can demonstrate low levels of this protein [17]. Hence, detection of *FOSL1* rearrangements by targeted sequencing approaches may be the preferred adjunct for the diagnostic work-up of fibrous tumours: this resolves the challenge of interpreting equivocal immunohistochemistry while

simultaneously identifying genetic alterations that may indicate other fibrous tumours, including desmoid-type fibromatosis, nodular fasciitis and low-grade fibromyxoid sarcoma.

Earlier genetic studies of desmoplastic fibroblastoma identified somatic changes in the vicinity of the *FOSL1* locus, associated with FOSL1 immunoreactivity [9,10]. Whole-genome and RNA sequencing enabled us to unravel the underlying somatic genetic alteration that explained these findings. In a remarkable parallel to rearrangements observed in *FOS*, translocations remove the regulatory region of *FOSL1* to generate a mutant gene mimicking the potent oncogene *v-fos* [4]. The regulatory region of *FOSL1* encodes motifs that are highly conserved across all *FOS* genes and promote protein degradation [18–20]. Disruption of these motifs is hypothesised to increase activity by increasing protein life span [6], which in the case of *FOS* has been corroborated experimentally *in vitro* [21]. It is thus highly plausible that *FOSL1* rearrangements operate through the same mechanism, i.e. reduced FOSL1 protein degradation, which is supported by our finding of intense FOSL1 protein immunoreactivity in mutant tumours.

Since systematic large-scale efforts to investigate human neoplasms have concluded, the somatic genetic landscape of the majority of tumour types has been defined. Precision medicine programmes, such as whole-genome sequencing offered to children with tumours and all patients with sarcoma, by the National Health Service in England [11] provide an opportunity to study genetically uncharted neoplasms in a real-life clinical context. As three of four *FOS* genes have emerged as recurrently mutated in human tumours, and given the structural and functional similarities between members of this gene family, we suspect that there may well be neoplasms harbouring yet undiscovered alterations in *FOSL2*, which clinical sequencing programmes of rare tumours can help reveal.

Acknowledgements

We thank the clinical teams of the Cambridge University Hospitals NHS Foundation Trust and London Sarcoma Service, as well as the East Genomics Laboratory Hub and the Institute of Cancer Research. We are grateful to the Biobank Team at the RNOH and Robert Jones and Agnes Hunt Orthopaedic Hospital. We specifically wish to thank all our patients and their families for participating in our research. We are indebted to patients and their carers.

This study was funded by Wellcome (fellowship to SB), Tom Prince Cancer Trust (AMF), Sarcoma UK (SUKG01.18), the Bone Cancer Research Trust and a Royal National Orthopaedic Hospital NHS R&D grant. AMF is supported by the National Institute for Health Research, UCLH Biomedical Research Centre and the UCL Experimental Cancer Centre. SDN holds a Jean Shanks Foundation & Pathological Society Clinical PhD fellowship. DH is funded by Cancer Research UK

CRUK (Stratified Medicine Paediatrics programme). The Clinical Genomics laboratory at the Royal Marsden is supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre.

Author contributions statement

RP, JT, JAT, JW and PT performed sequencing and analysis of the index case. PT, DH, MH and SDN performed sequencing and analysis of the validation cohorts. SB and MF contributed to bioinformatic analyses. RT, FA, JW, MM and NC were involved in clinical and pathological interpretations. HY and EM performed FISH analysis. AMF and SDN identified the validation cohort and evaluated the immunohistochemical results. SDN wrote the manuscript, with contributions from DH, AMF and SB. AMF and SB directed this research.

Data availability statement

The authors declare that all data supporting the findings of this study are available within the article and its supplementary information files or from the corresponding author on reasonable request.

References

- Curran T, MacConnell WP, van Straaten F, *et al.* Structure of the FBI murine osteosarcoma virus genome: molecular cloning of its associated helper virus and the cellular homolog of the *v-fos* gene from mouse and human cells. *Mol Cell Biol* 1983; **3**: 914–921.
- Jochum W, Passequé E, Wagner EF. AP-1 in mouse development and tumorigenesis. *Oncogene* 2001; **20**: 2401–2412.
- Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. *Immunol Rev* 2005; **208**: 126–140.
- Fittall MW, Mifsud W, Pillay N, *et al.* Recurrent rearrangements of *FOS* and *FOSB* define osteoblastoma. *Nat Commun* 2018; **9**: 2150.
- Antonescu CR, Chen HW, Zhang L, *et al.* ZFP36-FOSB fusion defines a subset of epithelioid hemangioma with atypical features. *Genes Chromosomes Cancer* 2014; **53**: 951–959.
- van IJzendoorn DGP, de Jong D, Romagosa C, *et al.* Fusion events lead to truncation of FOS in epithelioid hemangioma of bone. *Genes Chromosomes Cancer* 2015; **54**: 565–574.
- Walther C, Tayebwa J, Lilljebjöm H, *et al.* A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangi endothelioma. *J Pathol* 2014; **232**: 534–540.
- Kato I, Yoshida A, Ikegami M, *et al.* FOSL1 immunohistochemistry clarifies the distinction between desmoplastic fibroblastoma and fibroma of tendon sheath. *Histopathology* 2016; **69**: 1012–1020.
- Macchia G, Trombetta D, Möller E, *et al.* FOSL1 as a candidate target gene for 11q12 rearrangements in desmoplastic fibroblastoma. *Lab Invest* 2012; **92**: 735–743.
- Nakayama S, Nishio J, Aoki M, *et al.* An update on clinicopathological, imaging and genetic features of desmoplastic fibroblastoma (collagenous fibroma). *In Vivo* 2021; **35**: 69–73.
- Trotman J, Armstrong R, Firth H, *et al.* The NHS England 100,000 Genomes Project: feasibility and utility of centralised genome sequencing for children with cancer. *Br J Cancer* 2022; **127**: 137–144.

12. Uhrig S, Ellermann J, Walther T, *et al.* Accurate and efficient detection of gene fusions from RNA sequencing data. *Genome Res* 2021; **31**: 448–460.
 13. Robinson JT, Thorvaldsdóttir H, Wenger AM, *et al.* Variant review with the integrative genomics viewer. *Cancer Res* 2017; **77**: e31–e34.
 14. Pižem J, Matjašič A, Zupan A, *et al.* Fibroma of tendon sheath is defined by a USP6 gene fusion-morphologic and molecular reappraisal of the entity. *Mod Pathol* 2021; **34**: 1876–1888.
 15. Sugita S, Hirano H, Kikuchi N, *et al.* Diagnostic utility of FOSB immunohistochemistry in pseudomyogenic hemangioendothelioma and its histological mimics. *Diagn Pathol* 2016; **11**: 75.
 16. Amary F, Markert E, Berisha F, *et al.* FOS expression in osteoid osteoma and osteoblastoma: a valuable ancillary diagnostic tool. *Am J Surg Pathol* 2019; **43**: 1661–1667.
 17. Sobolev VV, Khashukoeva AZ, Evina OE, *et al.* Role of the transcription factor FOXL1 in organ development and tumorigenesis. *Int J Mol Sci* 2022; **23**: 1521.
 18. Acquaviva C, Brockly F, Ferrara P, *et al.* Identification of a C-terminal tripeptide motif involved in the control of rapid proteasomal degradation of c-Fos proto-oncoprotein during the G(0)-to-S phase transition. *Oncogene* 2001; **20**: 7563–7572.
 19. Basbous J, Chalbos D, Hipskind R, *et al.* Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. *Mol Cell Biol* 2007; **27**: 3936–3950.
 20. Grosset C, Chen CY, Xu N, *et al.* A mechanism for translationally coupled mRNA turnover: interaction between the poly(A) tail and a c-fos RNA coding determinant via a protein complex. *Cell* 2000; **103**: 29–40.
 21. van IJzendoorn DGP, Forghany Z, Liebelt F, *et al.* Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis. *J Biol Chem* 2017; **292**: 21282–21290.
 22. Amary MFC, Berisha F, Bernardi Fdel C, *et al.* Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. *Mod Pathol* 2007; **20**: 482–496.
- Reference 22 is cited only in the supplementary material.

SUPPLEMENTARY MATERIAL ONLINE

Supplementary materials and methods

Table S1. Summary of clinical demographics and immunohistochemical, FISH and targeted RNA sequencing results for validation cohort

Table S2. *FOXL1* and *FOS* breakpoints identified on targeted RNA sequencing